Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4642 | pathogen reduced SARS-CoV-2 convalescent plasma Wiki | 0.71 |
| drug3405 | Ruxolitinib Oral Tablet Wiki | 0.50 |
| drug2616 | Normal Saline Wiki | 0.29 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.06 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.06 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.05 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in healthy participants.
Description: Incidence and severity of other adverse events and severe adverse events (SAE)
Measure: Number of Participants Having Adverse Events Time: 29 DaysDescription: transfusion-related adverse events
Measure: Number of Participants Having Transfusion-Related Adverse Events Time: 29 DaysDescription: Incidence and severity of adverse events and SAEs from Screening through Study Day 90
Measure: Number of Participants Having Adverse Events Time: 90 DaysDescription: SARS-CoV-2 binding (ELISA) and neutralizing (PRNT80) antibody titers from Screening through Study Day 90
Measure: Pharmacokinetics from screening to day 90 Time: 90 Days: Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185, an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived), as a potential therapeutic to treat COVID-19. This study will evaluate the safety, immunogenicity, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19.
Description: Incidence and severity of other adverse events and severe adverse events (SAE)
Measure: Number of Participants Having Adverse Events Time: 29 DaysDescription: transfusion-related adverse events
Measure: Number of Participants Having Transfusion-Related Adverse Events Time: 29 DaysDescription: Incidence and severity of adverse events and SAEs from Screening through Study Day 90
Measure: Number of Participants Having Adverse Events Time: 90 DaysDescription: Measurement of SARS CoV-2 neutralizing (PRNT80) antibody titers from screening through Study Day 90
Measure: Assesment of the PD of SAB-185 administered intravenously Time: 90 DaysDescription: Measurement of Rheumatoid factor through day 90
Measure: Immune response elicited by SAB-185 Time: 90 DaysDescription: Measurement of anti-SAB-185 antibodies through screening day 90
Measure: Concentration of subject anti-SAB-185 antibodies elicited by SAB-185 Time: 90 DaysDescription: Incidence of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29
Measure: Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Time: 29 DaysDescription: Level of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29
Measure: Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens Time: 29 DaysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports